Dr Hannah Wardill is internationally recognised in the field of supportive oncology research. Her program, which involves both laboratory and clinical research, aims to prevent the long-term disadvantages inflicted by cancer and its treatment by developing supportive care solutions that meet the unique needs of the patient.
The Supportive Oncology Research Group, started by Hannah in 2020, has so far received over $12 million in funding. This includes $4.2 million from the Medical Research Future Fund for two landmark trials in Australia.
Hannah has held many leadership roles and as board member for the Multinational Association for Supportive Care in Cancer, she was instrumental in the creation of the Association’s first framework for more effective engagement with patients, advocates and people with lived experiences.
Hannah’s work has been prolific and highly impactful: she has published more than 85 peer-reviewed articles, received numerous awards and won more than $15 million in funding.